Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 801–900 of 1,000
Xiao, Z., Li, P., Shen, Y., Manaenko, A., Yang, W., Wang, P., Li, X., Liu, F., Xie, P., & Li, Q. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114507 · Cited by 5
Advances in Prehospital Management of Intracerebral Hemorrhage
Gioia, L. C., Mendes, G. N. N., Poppe, A. Y., & Stapf, C. (2024) · Cerebrovascular Diseases · doi:10.1159/000537998 · Cited by 5
Anderson, C. S., & Selim, M. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198864714.003.0018 · Cited by 5
Sonothrombolysis: An Emerging Modality for the Treatment of Acute Ischemic and Hemorrhagic Stroke
Soltani, A., Clark, W. M., & Hansmann, D. R. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0077-1 · Cited by 5
“Currently, two approaches are under further evaluation for treatment of ICH: (1) administration of activated recombinant factor VII, NovoSeven® (Novo Nordisk A/S, Bagsvaerd, Denmark), for preventing early hematoma growth in acute ICH patients presenting within 4 h after symptom onset [36] and (2) clot removal by trans…”
MethodAlternative Clinical Trial Design in Neurocritical Care
Lazaridis, C., Maas, A. I. R., Souter, M. J., Martin, R. H., Chesnut, R. M., DeSantis, S. M., Sung, G. Y., LeRoux, P. D., & Suárez, J. I. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0135-8 · Cited by 6
“among others [3–6].”
Advances in CT for prediction of hematoma expansion in acute intracerebral hemorrhage
Huynh, T. J., Symons, S. P., & Aviv, R. I. (2013) · Imaging in Medicine · doi:10.2217/iim.13.64 · Cited by 5
“Both rFVIIa and acute BP reduction treatments have demonstrated their ability to reduce absolute and relative hematoma growth; however, both treatment strategies have failed to translate effects of reduced expansion into improvements in 3-month clinical outcome [13,15,31].”
Biomarkers in Neurocritical Care
Kimberly, W. T. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0089-2 · Cited by 5
“Although a statistically significant decrease in hematoma expansion was demonstrated with treatment, there was no difference in clinical outcome [34].”
Diagnosis and Management of Acute Ischemic Stroke
Gorelick, P. B., & Ruland, S. D. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2009.12.003 · Cited by 6
Zeng, L., Guo, J., Wang, J., Zhang, Q., Li, H., & Lin, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-3136-y · Cited by 5
“Furthermore, it has been confirmed that neither mini-traumatic operation nor the present accessible medicine is proved to be the ideal treatment based on the available evidencebased medical researches (Morgenstern et al. 2010; Mendelow et al. 2013; Mayer et al. 2008).”
Chen, J., Zhang, D., Li, Z., Dong, Y., Han, K., Wang, J., & Hou, L. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.11.149 · Cited by 5
Miki, K., Abe, H., Nonaka, M., Morishita, T., Iwaasa, M., Arima, H., & Inoue, T. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.08.244 · Cited by 5
Gupta, K., & Das, J. M. (2019) · StatPearls · Cited by 5
Xu, M., Cheng, Y., Zhang, S., Zhang, S., Song, Q., Zheng, L., Liu, M., & Liu, M. (2021) · Microcirculation · doi:10.1111/micc.12705 · Cited by 6
A Historical Perspective on the Reversal of Anticoagulants
Salter, B., & Crowther, M. A. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1753485 · Cited by 6
Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery
Culley, C. M., Guttendorf, S., Coldren, M., Skledar, S. J., Gross, P. R., Spiro, R. M., Triulzi, D. J., & Ragni, M. V. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080367 · Cited by 5
Greenberg, S. M., Grotta, J. C., & Xi, G. (2010) · Stroke · doi:10.1161/strokeaha.110.595041 · Cited by 5
Current treatment options for intracerebral hemorrhage
Rincón, F., & Mayer, S. A. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0025-x · Cited by 6
Self-citationTherapeutic Hypothermia in Brain Injury
(2013) · InTech eBooks · doi:10.5772/3380 · Cited by 6
Intracerebral hematoma expansion
Chaturvedi, S., & Greenberg, S. M. (2011) · Neurology · doi:10.1212/wnl.0b013e31821435d0 · Cited by 5
Marlu, R., Hodaj, E., & Pernod, G. (2012) · Circulation · doi:10.1161/circulationaha.111.073122 · Cited by 5
CLEAR Intraventricular Hemorrhage
Mattle, H. P., & Raabe, A. (2011) · Stroke · doi:10.1161/strokeaha.111.628024 · Cited by 5
Risk for Intracerebral Hematoma Expansion—More Than Just the Spot Sign
Smith, E. E. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3048 · Cited by 5
Off-Protocol Access to Study Therapies
Cochrane, T. I. (2013) · Topics in Stroke Rehabilitation · doi:10.1310/tsr2001-1 · Cited by 4
Shakya, M. R., Zheng, C., Fu, F., Sun, S., & Lu, J. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.08.035 · Cited by 4
Colasurdo, M., Amran, D., Chen, H. A., Ziv, K., Geron, M., Love, C. J., Robledo, A., O’Leary, S., Husain, A., von Waaden, N., et al. (2025) · Neurosurgery · doi:10.1227/neu.0000000000003455 · Cited by 4
Ultra-early computed tomography markers of haematoma expansion: Potential trial targets?
Mutimer, C. A., Sharma, S., Zhao, H. H., Meretoja, A., Churilov, L. P., Wu, T. Y., Kleinig, T. J., Choi, P. M. C., Cheung, A. K., Jeng, J., et al. (2025) · European Stroke Journal · doi:10.1093/esj/23969873251355938 · Cited by 4
“17 Poor functional outcome at 90-days was defined as mRS 3–6.”
Self-citationInflammation and White Matter Injury in Animal Models of Ischemic Stroke
Schlichter, L. C., Hutchings, S., & Lively, S. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9123-1_19 · Cited by 5
Masotti, L., Pampana, A., Pennati, P., & Landini, G. (2010) · Italian Journal of Medicine · doi:10.1016/j.itjm.2010.07.009 · Cited by 4
“Introdotto in commercio come farmaco per il trattamento dell’emofilia, il fattore VII ricombinante attivato (FVIIra), prodotto di sintesi, è stato valutato nel trattamento dell’EICTAO associata e non TAO associata con discreti risultati in termini di efficacia, ma è gravato da un aumento del tasso di complicanze tromb…”
BackgroundStroke: acute stroke receiving facilities and management
Humpich, M. C., Byhahn, C., Fowler, R. L., & Labiche, L. A. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32832e4566 · Cited by 4
Pre-Hospital Glyceryl Trinitrate: Potential for Use in Intracerebral Hemorrhage
Chang, J. J. (2013) · Journal of Neurological Disorders · doi:10.4172/2329-6895.1000141 · Cited by 4
“While promoting coagulation has the potential for reducing expansion, it has not been shown to improve outcome or reduce disability [8].”
Willis, C. D., Cameron, P. A., & Phillips, L. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03632.x · Cited by 5
Managing Subdural Bleeding Associated With Rivaroxaban
Faust, A. C., Woodard, S., Koehl, J. L., Mees, W., Steinke, D. T., & Denetclaw, T. H. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190015627116 · Cited by 4
Katsanos, A. H., Gupta, H., Morotti, A., Beshara, S. P., Patil, T., Al-Zahrani, S., Tsivgoulis, G. K., Dowlatshahi, D. D., Goldstein, J. N., Charidimou, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061596 · Cited by 4
Sim, D., Mallari, C. R., Teare, J. M., Bauzon, M., & Hermiston, T. W. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.05.007 · Cited by 4
Wang, Y., Yuan, Z., Zhang, Z., Shang, J., Li, M., & Wang, W. (2022) · Applied Bionics and Biomechanics · doi:10.1155/2022/9808334 · Cited by 4
“Several large clinical trials [20, 21] have focused on reducing hematoma dilatation through a rigorous treatment window; most of them occurs within 24 hours of the onset of ICH.”
BackgroundRetractedWhat are the next breakthroughs in the management of acute intracerebral hemorrhage?
Toyoda, Ḱ., Koga, M., & Sato, S. (2016) · International Journal of Stroke · doi:10.1177/1747493016631559 · Cited by 4
“In the Factor Seven for Acute Hemorrhagic Stroke Trial (FAST), emergent administration of recombinant activated factor VII reduced early hematoma growth, but it did not improve clinical outcomes.(6) Selection of eligible patients using the spot sign on computed tomography angiography or other biomarkers for hematoma g…”
BackgroundFeng, C., Huang, S., Zhou, X., Wang, L., Cui, X., Chen, L., Lv, F., & Li, T. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.08.021 · Cited by 4
Optimizing Emergency Stroke Transport Strategies Using Physiological Models
Paydarfar, D. A., Paydarfar, D., Mucha, P. J., & Chang, J. (2021) · Stroke · doi:10.1161/strokeaha.120.031633 · Cited by 4
He, Q., Zhou, Y., Liu, C., Chen, Z., Wen, R., Wu, Y., Xie, Z., Cheng, Y. Z., & Cheng, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.746024 · Cited by 5
“with placebo, but did not improve survival or functional outcomes (6, 32).”
BackgroundBhatia, R., Shobha, N., Bermejo, P. G., & Dowlatshahi, D. D. (2019) · Springer eBooks · doi:10.1007/978-981-13-5866-1_12 · Cited by 4
Le facteur VII recombinant activé en pédiatrie. Hémostatique universel ?
Monpoux, F., Chambost, H., Haouy, S., Benadiba, J., & Sirvent, N. (2010) · Archives de Pédiatrie · doi:10.1016/j.arcped.2010.05.018 · Cited by 4
Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
AlGahtani, F. H., Alshaikh, M. K., & AlDiab, A. (2010) · Annals of Saudi Medicine · doi:10.4103/0256-4947.62830 · Cited by 4
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
Yampolsky, N., Stofko, D. L., Veznedaroglu, E., Liebman, K. M., & Binning, M. J. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-471 · Cited by 4
“%) with no added benefit for reduction in mortality rates or improved survival outcomes (Howes et al. 2009; MacLaren et al. 2005; Mayer et al. 2008).”
BackgroundAn evidence-based approach to managing the anticoagulated patient in the emergency department.
Hanlon, D. P. (2011) · PubMed · Cited by 4
Surgical Management of Intracerebral Hemorrhage
Aghi, M. K., Ogilvy, C. S., & Carter, B. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6839-6.10069-3 · Cited by 4
Spontaneous Intracerebral Hemorrhage
Hoffer, A., Singer, J. A., Bambakidis, N. C., & Selman, W. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0701-4.00016-6 · Cited by 4
rFVIIa and NN1731 Reduce Bleeding in Hydroxyethyl Starch Hemodiluted Rabbits
Lauritzen, B., Viuff, D., Tranholm, M., & Ezban, M. (2010) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181c6619d · Cited by 4
Yao, Y., Wu, J., Zhao, W., Zhao, L., Zhu, C., & Gao, X. (2015) · Journal of International Medical Research · doi:10.1177/0300060514565801 · Cited by 4
Brain Edema in Neurological Diseases
Candelario‐Jalil, E., Taheri, S., & Rosenberg, G. A. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_5 · Cited by 4
“A subsequent study failed to confirm the results of the first because of a high rate of thrombotic complications (Mayer et al., 2008).”
ResultRendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Thalji, N. K., & Camire, R. M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000369 · Cited by 4
Serum Glial Fibrillary Acidic Protein in Acute Stroke
Seder, D. B. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00942-2 · Cited by 4
Acute Spontaneous Intracerebral Hemorrhage Management Update: Five New Things You Should Know
Phung, J. Y. H., Yogendrakumar, V., & Dowlatshahi, D. D. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_174_25 · Cited by 3
“[25] ]”
Abraham, D. I., Kellner, C. P., Polymeris, A. A., Poyraz, F. C., Heistand, E. C., Marchal, J., Lazar, A., Lioutas, V., Mocco, J., & Selim, M. H. (2025) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2025-023804 · Cited by 3
Qureshi, A. I., Abou‐Hamden, A., Morotti, A., Mould, A., Molina, C. A., Klijn, C. J. M., Kellner, C. P., Anderson, C. S., Rubio, D. R., Seiffge, D. J., et al. (2025) · Stroke · doi:10.1161/strokeaha.125.052984 · Cited by 3
Self-citationTreatment of Hemorrhagic Stroke
Kramer, A. H. (2013) · Stroke · doi:10.1002/9781118560730.ch5 · Cited by 3
Scultetus, A. H., Arnaud, F. G., Kaplan, L. J., Shander, A., Philbin, N. B., Rice, J., McCarron, R. M., & Freilich, D. (2010) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199.2010.501755 · Cited by 3
Prothrombotic recombinant activated factor VII in intracerebral haemorrhage: FAST but not focused?
Bogousslavsky, J., & Piechowski‐Jóźwiak, B. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70147-9 · Cited by 3
DISORDERS INVOLVING ABNORMAL COAGULATION
Caplan, L. R., & Bogousslavsky, J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544897.039 · Cited by 3
Pemmaraju, N., Sasaki, K., Johnson, D. A., Daver, N. G., Afshar‐Kharghan, V., Chen, M., Ahmed, S., Colen, R. R., Kwon, M. C., Huh, Y. O., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00029 · Cited by 3
“However, subsequent studies have revealed conflicting evidence regarding the effectiveness of early rFVIIa use, confirming reduced hematoma size in patients who received rFVIIa but were unable to exhibit reduced mortality or improved functional outcomes after ICH (7).”
ResultBeyond Therapeutic Nihilism? The Neurosurgical Treatment of Intracerebral Hemorrhage
Willie, J. T., & Gross, R. E. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.01.029 · Cited by 3
UPDATE ON INTRACEREBRAL HEMORRHAGE
Diringer, M. N. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000348822.26996.32 · Cited by 3
“Subsequent to this study, a phase 3 clinical outcome trial was performed (Mayer et al, 2008).”
MethodSelf-citationAdvances in pre-hospital care - operational experiences from the Melbourne mobile stroke unit
Zhao, H. H., Campbell, B. C. V., Foster, S., Stephenson, M., Coote, S., Langenberg, F., Easton, D., Donnan, G. A., & Davis, S. M. (2021) · Vessel Plus · doi:10.20517/2574-1209.2020.77 · Cited by 3
Self-citationPrognostic Neuroimaging Biomarkers in Acute Vascular Brain Injury and Traumatic Brain Injury
Krawchuk, L. J., & Sharrock, M. F. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1775790 · Cited by 3
Ultra-Early Hemostatic Therapy for Acute Intracerebral Hemorrhage: An Updated Review
Fortunato, M. P., Subah, G., Thomas, A. D., Nolan, B. E., Mureb, M., Uddin, A., Upadhyay, K., Ogulnick, J. V., Damodara, N., Bond, C., et al. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000675 · Cited by 3
Self-citationLing, Y., Tariq, M. B., Tang, K., Aronowski, J. A., Fann, Y. C., Savitz, S. I., Jiang, X., & Kim, Y. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000493 · Cited by 3
“[10–13] Recently, an international multicenter Phase III trial evaluated a care bundle protocol to improve a patient’s functional outcome after an acute ICH disease.”
BackgroundSieh, L., Peasley, E., Mao, E., Mitchell, A., Heinonen, G., Ghoshal, S., Agarwal, S., Park, S., Connolly, E. S., Claassen, J., et al. (2024) · Neurocritical Care · doi:10.1007/s12028-024-02051-w · Cited by 3
“However, these interventions did not improve outcomes [15, 16] and even caused harm [17].”
Is spot sign the answer for intracerebral haemorrhage?
Romero, J. M. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.93 · Cited by 3
Head Trauma – Anesthesia Considerations and Management
Tenenbein, P., Kincaid, M. S., & Lam, A. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547447.014 · Cited by 3
Secondary Prevention of Cardioembolic Stroke
Aguilar, M. I., & Benavente, O. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5478-8.10059-4 · Cited by 3
Arikán, F., Urzaiz, L. L., Alén, J. F., & Laez, R. M. (2017) · Neurocirugía · doi:10.1016/j.neucir.2017.08.001 · Cited by 3
Altıntaş, Ö., Niftaliyev, E., & Asıl, T. (2018) · Neurological Research · doi:10.1080/01616412.2018.1517111 · Cited by 3
“Indeed, FAST trial (The Factor Seven for Acute Hemorrhagic Stroke) was showed that recombinant FVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after ICH [22].”
BackgroundInfluentialNaidech, A. M., Lawlor, P. N., Xu, H., Fonarow, G. C., Xian, Y., Smith, E. E., Schwamm, L. H., Matsouaka, R., Prabhakaran, S., Marinescu, I., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00961 · Cited by 3
“, shortening the window of recombinant Factor VII for intracerebral hemorrhage from 3 h of symptom onset (8) to 2.”
BackgroundChen, Y., Chang, J., Wei, J., Feng, M., & Wang, R. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00828-y · Cited by 3
Akıncı, Y., & Qureshi, A. I. (2021) · Vessel Plus · doi:10.20517/2574-1209.2021.20 · Cited by 3
Covrig, R.-C., Schellinger, P. D., Glahn, J., Al-Omari, A., Schmieder, K., Wiese, M., & Knappe, U. J. (2022) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/s-0041-1741546 · Cited by 4
Patel, P. V., Elijovich, L., & Hemphill, J. C. (2012) · Springer eBooks · doi:10.1007/978-0-387-88585-8_9 · Cited by 4
Delcourt, C., & Anderson, C. S. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198739555.003.0019 · Cited by 3
Cáceres, E. L., Salazar, P., Shidoh, S., Ortiz, M. J., Bragin, D. E., Kibria, F., & Divani, A. A. (2025) · Neurocritical Care · doi:10.1007/s12028-024-02195-9 · Cited by 3
Delcourt, C., Stapf, C., Tzourio, C., Heritier, S. R., & Anderson, C. S. (2011) · Revue Neurologique · doi:10.1016/j.neurol.2011.08.010 · Cited by 3
Worster, A., Keim, S. M., Carpenter, C. R., & Adeoye, O. M. (2009) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2009.05.002 · Cited by 3
Hypertensiveintracerebral hemorrhage
Burke, J. F., & Jacobs, T. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997426.087 · Cited by 3
Stroke: success for extending acute treatment
Lees, K. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70270-9 · Cited by 3
Controversies in Neurosciences Critical Care
Chang, T. R., Naval, N. S., & Carhuapoma, J. R. (2012) · Anesthesiology Clinics · doi:10.1016/j.anclin.2012.05.006 · Cited by 4
Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors
Karli, B., Bartel, B. J., & Pavelko, R. (2015) · Hospital Pharmacy · doi:10.1310/hpj5007-569 · Cited by 3
Rivera-Fernández, R., Guerrero-López, F., Rodríguez-Rubio, D., Gómez-Jiménez, F. J., Rodríguez-Vilanova, F., Mora-Ordóñez, J. M., Olea-Jiménez, V., Arias-Verdú, M. D., Quesada-García, G., Acebal-Blanco, F., et al. (2016) · Neurocirugía · doi:10.1016/j.neucir.2016.01.003 · Cited by 3
Acute Management of Anticoagulation-Associated Intracerebral Hemorrhage
Kuramatsu, J. B., Gerner, S. T., Huttner, H. B., & Schwab, S. (2017) · Neurology International Open · doi:10.1055/s-0043-108836 · Cited by 3
“Due to the negative results, safety concerns, and an increased rate of thromboembolic complications in the FAST trial, which was a phase III study on the efficacy of recombinant activated factor VII (rFVIIa) in ICH patients, the administration of rFVIIa is not recommended at this time [1, 61].”
BackgroundIntracerebral haemorrhage is hard to stop, and must be attacked before, during and after
Tirschwell, D. (2018) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111083 · Cited by 3
“The recombinant factor VIIa trials showed promise, but then a larger trial targeting early presenting patients did significantly reduce ICH growth but failed to demonstrate a significant clinical benefit.(3) The INTERACT 2 trial showed that intensive BP management (goal systolic BP (SBP) <140) versus standard BP manag…”
BackgroundYogendrakumar, V., Moores, M., Sikora, L., Ramsay, T., Fergusson, D. A., & Dowlatshahi, D. D. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024744 · Cited by 3
Management intrazerebraler Blutungen
Staykov, D., Köhrmann, M., & Unterberg, A. W. (2012) · Der Nervenarzt · doi:10.1007/s00115-012-3531-8 · Cited by 3
Targeting hematoma expansion in ICH
Haussen, D. C., & Selim, M. H. (2012) · Neurology · doi:10.1212/wnl.0b013e318260cda7 · Cited by 3
Relative risks of recombinant factor VII*
McMullan, D. M. (2009) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181ae49e1 · Cited by 3
Treatment of Intracerebral Hemorrhage—Is the Glass Half Full or Half Empty?
Morgenstern, L. B. (2012) · Translational Stroke Research · doi:10.1007/s12975-012-0179-4 · Cited by 3
“An unselected approach failed to pass the risk/benefit test [3], but ongoing studies selecting patients with documented active bleeding and low risk of vascular ischemia may be the way to go [4].”
Optimizing emergency stroke transport strategies using physiological models
Paydarfar, D. A. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rbrv-sq26 · Cited by 3
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
Kreutziger, J., Ulmer, H., & Fries, D. R. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407378 · Cited by 3
Hematoma Expansion in Intracerebral Hemorrhage: Time Is the Enemy
Fandler‐Höfler, S., & Murthy, S. B. (2025) · Stroke · doi:10.1161/strokeaha.125.050756 · Cited by 3
Petros, S. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-015-0138-4 · Cited by 2
“Eine große Studie an Patienten nach intrazerebraler Blutung zeigte zwar eine Reduktion des Hämatomwachstums unter rFVIIa-Gabe, jedoch ohne Vorteil hinsichtlich des Überlebens und der neurologischen Funktion [41].”
Vascular Diseases of the Nervous System
Kase, C. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7506-7525-3.50070-4 · Cited by 2
Sun, Z., Zhou, X., Xiang, J., Wang, F., Han, Y., Guo, Y., Zhang, Z., Gong, F., Wang, M., Liu, D., et al. (2025) · Stroke and Vascular Neurology · doi:10.1136/svn-2024-003931 · Cited by 2
“An independent statistician generated randomisation allocations using SAS V.9.4 at a ratio of 1:1 using a block design (block size, 4), and the participants were stratified by centre to ensure balanced allocation across sites.”
InfluentialWang, C., Fan, R., Lin, Z., Chen, S., Pan, C., Nie, H., Qin, C., Wu, X., & Tang, Z. (2025) · Research · doi:10.34133/research.1083 · Cited by 2
“Several large RCTs (e.g., the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial) have shown that although rFVIIa reduces the risk of hematoma expansion, it fails to improve long-term neurological outcomes or mortality rates [ 150 ].”
Location‐Specific Analysis of Hematoma Expansion in Intracerebral Hemorrhage
Ho, R. W.-H., Cai, J., Hu, Y., So, C. H., Leung, K., Wu, J., Lui, A., Wang, W., Xiao, H., Zeng, W., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042399 · Cited by 2
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.